Compare ACADIA Pharmaceuticals Inc. (ACAD) vs YieldMax AMD Option Income Strategy ETF (AMDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs YieldMax AMD Option Income Strategy ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while YieldMax AMD Option Income Strategy ETF trades at $52.94. Which is the better fit depends on your goals.
| ACAD | AMDY | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $28.06 | $59.52 |
52-Week Low | $20.06 | $29.80 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AMDY trades at $56.10, up 5.35% in the last 24 hours, with technical indicators showing a bullish trend. The stock exhibits strong weekly dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights high-yield potential alongside concerns over net asset value erosion due to its option income strategy.
The outlook for AMDY is mixed; high dividend yields attract income investors, but structural risks from NAV erosion and dependency on AMD's stock performance pose significant challenges. Investors should weigh the income benefits against potential capital depreciation in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →
